Owlet
OWLTNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $4.62 Prior regular-session close from the quote source.
- $2.75–$3.63 Regular-session low and high so far today.
- 2.3M Regular-session shares traded · Nov 13, 4:00 PM ET.
- Mar 4 projected Projected for 2027-03-04 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $2.75–$16.94 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own OWLT if its regulated health positioning converts anxious-parent demand into profitable scale before cash burn or competition closes the window.
OWLT price history
Loading recent earnings…
Investment thesis
What must happen next
Owlet’s differentiated pediatric-health positioning can rebuild parent trust and convert infant-monitoring anxiety into demand, but this claim needs calibration because recent full-year revenue after 2023 is not supplied.HoldingMateriality: High
Item 1-derived profile description calls Owlet a leading pediatric health platform and says it is the only company globally to offer a U.S. pediatric health-platform product, indicating the company is competing on regulated health differentiation rather than generic baby monitoring. If the trust advantage converts, Owlet can grow from a small base; if it does not, the company remains a niche hardware vendor with limited scale.
Watch: A new FDA warning, product recall, or safety controversy undermines the trust that makes a health-positioned infant monitor different from a normal baby camera.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1-derived profile description calls Owlet a leading pediatric health platform and says it is the only company globally to.
Open source ↗Owlet’s health-monitoring differentiation must support premium pricing and acceptable hardware economics despite consumer-electronics competition.HoldingMateriality: High
GAAP annual gross profit was $22.6 million in FY2023 on $54.0 million of revenue, implying a gross margin of about 41.8%. Revenue growth only creates owner value if Owlet can avoid discount-led volume and keep enough gross profit to fund R&D, support, compliance, and marketing.
Watch: Amazon marketplace, big-box retail, or direct-to-consumer price competition forces Owlet into sustained promotions to defend unit volume.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit was $22.6 million in FY2023 on $54.0 million of revenue, implying a gross margin of about.
Open source ↗A focused operating model can convert any revenue recovery into operating leverage because Owlet has already reduced cash consumption materially.StrengtheningMateriality: Medium
GAAP annual operating cash flow improved from negative $81.4 million in FY2022 to negative $23.5 million in FY2023. If the lean model holds, Owlet can survive to scale; if growth requires a large re-expansion of spending, shareholders face renewed financing risk.
Watch: Owlet must rebuild a large direct-to-consumer marketing engine or clinical sales force to restart growth.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow improved from negative $81.4 million in FY2022 to negative $23.5 million in FY2023.
Open source ↗Owlet has enough balance-sheet runway to pursue the pediatric-health turnaround only if cash burn stays near its reduced level and no major regulatory or product shock appears.StrengtheningMateriality: Medium
Cash and cash equivalents were $35.5 million at FY2025, up from $20.2 million at FY2024 and $16.6 million at FY2023. The upside belongs to shareholders only if Owlet avoids emergency capital raises, punitive debt, or dilution before reaching breakeven.
Watch: A recall, FDA remediation program, litigation settlement, or product-quality issue creates a cash need unrelated to normal growth spending.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash and cash equivalents were $35.5 million at FY2025, up from $20.2 million at FY2024 and $16.6 million at FY2023.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Owlet’s differentiated pediatric-health positioning can rebuild parent trust and convert infant-monitoring anxiety into demand, but this claim needs calibration because recent full-year revenue after 2023 is not supplied. If the trust advantage converts, Owlet can grow from a small base; if it does not, the company remains a niche hardware vendor with limited scale.
Owlet’s health-monitoring differentiation must support premium pricing and acceptable hardware economics despite consumer-electronics competition. Revenue growth only creates owner value if Owlet can avoid discount-led volume and keep enough gross profit to fund R&D, support, compliance, and marketing.
A focused operating model can convert any revenue recovery into operating leverage because Owlet has already reduced cash consumption materially. If the lean model holds, Owlet can survive to scale; if growth requires a large re-expansion of spending, shareholders face renewed financing risk.
Owlet has enough balance-sheet runway to pursue the pediatric-health turnaround only if cash burn stays near its reduced level and no major regulatory or product shock appears. The upside belongs to shareholders only if Owlet avoids emergency capital raises, punitive debt, or dilution before reaching breakeven.
All standing thesis claims
Original report summary
its regulated health positioning converts anxious-parent demand into profitable scale before cash burn or competition closes the window.
Bull case and bear case
Bull case and bear case for Owlet
Where the evidence on Owlet stands: Holding on the latest evidence (Nov 10, 2026). Of its 4 thesis points, 2 strengthening and 2 holding.
Bull case: what the evidence supports
Owlet’s differentiated pediatric-health positioning can rebuild parent trust and convert infant-monitoring anxiety into demand, but this claim needs calibration because recent full-year revenue after 2023 is not supplied.
Owlet’s health-monitoring differentiation must support premium pricing and acceptable hardware economics despite consumer-electronics competition.
A focused operating model can convert any revenue recovery into operating leverage because Owlet has already reduced cash consumption materially.
Owlet has enough balance-sheet runway to pursue the pediatric-health turnaround only if cash burn stays near its reduced level and no major regulatory or product shock appears.
Bear case: what would count against it
A new FDA warning, product recall, or safety controversy undermines the trust that makes a health-positioned infant monitor different from a normal baby camera.
Amazon marketplace, big-box retail, or direct-to-consumer price competition forces Owlet into sustained promotions to defend unit volume.
Owlet must rebuild a large direct-to-consumer marketing engine or clinical sales force to restart growth.
Thesis-Break Engine
Thesis-break watch · Owlet
No break has crossed Owlet’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedDirector or principal officer change.
Owlet filed an SEC 8-K on 2026-08-14: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Owlet filed an SEC 8-K on 2026-08-11: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Owlet filed an SEC 8-K on 2026-07-01: Entered a material definitive agreement. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A new FDA warning, product recall, or safety controversy undermines the trust that makes a health-positioned infant monitor different from a normal baby camera.
- Amazon marketplace, big-box retail, or direct-to-consumer price competition forces Owlet into sustained promotions to defend unit volume.
- Owlet must rebuild a large direct-to-consumer marketing engine or clinical sales force to restart growth.
- A recall, FDA remediation program, litigation settlement, or product-quality issue creates a cash need unrelated to normal growth spending.
OWLT news
Loading headlines…
Financial statements
OWLT income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
OWLT: quick answers
- When does Owlet (OWLT) report earnings next?
- Owlet's next results are projected for March 4, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 13, 2026. Earnings calendar
- What is OWLT's short interest?
- As of October 30, 2026, 431,949 OWLT shares were sold short, down 21.5% from the count before. At the stock's average daily volume that is 4.0 days to cover. FINRA publishes the count twice a month. OWLT short interest history